News Articles and Montana BioScience Alliance Newsletters
Montana’s Tonix Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that it has entered into a sponsored research agreement with Boston Children’s Hospital to study TNX-15001 (Fc-modified anti-CD40L mAb) for the prevention of graft-versus-host disease (GvHD) after hematopoietic stem cell transplantation (HCT) in animals.
The University of Montana recently secured $5.1 million in federal grants from the Health Resource and Service Administration, leading to the formation of a new UM Office of Health Research & Partnership. The office will use the HRSA funding for programs to bolster the health care workforce and increase access to quality health care in rural and underserved parts of Montana.
MSU Associate Professor of Molecular Biology Lynn George, Ph.D., was recently awarded a National Institutes of Health Academic Research Enhancement Award (AREA) from the National Institute of Neurological Disorders and Stroke. This three-year, $385,000 grant will support George’s efforts to continue and expand her research on Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease. George’s grant proposal scored in the top one percentile, which is laudable, given the highly competitive nature of NIH funding.
Montana State University has appointed Alison Harmon, its dean of the College of Education, Health and Human Development, as its interim vice president of research and economic development.
Billings’ next generation of medical professionals got a chance to get specific Friday, touring booths from dozens of different medical disciplines who all were trying to sway students their way.
Are you working to develop an innovative cancer technology? Take a step forward in your commercialization journey through the newly released FY2024 SBIR Contract Solicitation! This funding opportunity aims to provide early-stage funding to small businesses that are developing cancer technologies in areas defined by the National Cancer Institute.
The U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit.
The PHS 2023-2 omnibus solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications have been released. The first application due date is Tuesday, September 5, 2023.
The panel’s decision moves the U.S. one step closer to making jabs against respiratory syncytial virus available to the public this fall, when the disease typically begins to spread at higher levels.
The biennial report provides a national snapshot of the most pressing current and anticipated talent needs of the nation’s dynamic life science industry. This year’s report distills a set of key themes sourced from 185 executive interviews and nearly 700 survey responses from companies in eighteen states and Puerto Rico, as well as an assessment of nearly 2.8M job postings from life science companies over the last four years.
View the Summer 2023 Newsletter now!
View the Spring 2023 Newsletter now!